- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | BiomX announces 1-for-19 reverse stock split | 4 | Seeking Alpha | ||
| 14.11. | BiomX to implement 1-for-19 reverse stock split on November 25 | 1 | Investing.com | ||
| BIOMX Aktie jetzt für 0€ handeln | |||||
| 14.11. | BiomX Inc. Announces 1-for-19 Reverse Stock Split | 137 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting... ► Artikel lesen | |
| 12.11. | BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections | 2 | Seeking Alpha | ||
| 12.11. | BiomX GAAP EPS of $0.29 | 2 | Seeking Alpha | ||
| 12.11. | BiomX Inc: BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates | 295 | GlobeNewswire (Europe) | Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success BiomX expects FDA feedback on BX004 clinical... ► Artikel lesen | |
| 12.11. | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Earnings Preview For BiomX | 2 | Benzinga.com | ||
| 04.11. | BiomX Inc: BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections | 127 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting... ► Artikel lesen | |
| 17.10. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | BiomX addresses FDA queries on nebulizer for CF treatment | 4 | Investing.com | ||
| 17.10. | BiomX reagiert auf FDA-Anfragen zu Vernebler für Mukoviszidose-Therapie | 8 | Investing.com Deutsch | ||
| 17.10. | BiomX Inc: BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways | 5 | GlobeNewswire (USA) | ||
| 19.08. | BiomX Inc: BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis | 562 | GlobeNewswire (Europe) | U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification... ► Artikel lesen | |
| 13.08. | BiomX outlines BX004 Phase IIb results expected in Q1 2026 as BX211 advances toward registrational study | 1 | Seeking Alpha | ||
| 13.08. | BiomX Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | BiomX GAAP EPS of -$0.19 | 3 | Seeking Alpha | ||
| 13.08. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | BiomX Inc: BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates | 362 | GlobeNewswire (Europe) | Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications... ► Artikel lesen | |
| 12.08. | What to Expect from BiomX's Earnings | 1 | Benzinga.com |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,25 | +2,92 % | Ihre wichtigsten Termine: Heute im Fokus: Bertelsmann, Medtronic, Biontech, Rheinmetall & Imperial Brands | © Foto: Deutsche Börse AGGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:15... ► Artikel lesen | |
| AMGEN | 295,00 | +1,71 % | Dividendenbekanntmachungen (21.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,065 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,27 USD 0,2341 EUR ALPHAMIN... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,540 | -1,91 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 2,229 | +2,93 % | Pacific Biosciences: Mit Long-Read-Sequenzierung zum Angriff auf Illumina | ||
| CARDIOL THERAPEUTICS | 0,830 | -6,74 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 | Once issued, this new U.S. patent covers the use of CardiolRx and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,090 | +7,39 % | RedHill Biopharma Receives Nasdaq Staff Determination Notification | On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the minimum... ► Artikel lesen | |
| FIBROGEN | 7,350 | -2,65 % | XFRA 1FG0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| LEXAGENE | - | - | SOLARIA ENERGIA Y MEDIOAMBIENTE, S.A.: Solaria reports it has signed an agreement with Stoneshield Capital to create a new joint venture, Gravyx, specialising in standalone batteries. | ||
| VAXCYTE | 42,200 | -1,40 % | Vaxcyte: Leerink Partners hebt Kursziel deutlich auf 77 US-Dollar an | ||
| VERRICA PHARMACEUTICALS | 4,260 | +3,40 % | Verrica Pharmaceuticals announces $50M PIPE financing | ||
| HOOKIPA PHARMA | 0,870 | +3,55 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead | NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA") today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 4,555 | +2,71 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome | The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic... ► Artikel lesen | |
| ARCELLX | 73,06 | -2,53 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| QIAGEN | 41,790 | +1,79 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,55 | +0,53 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' |
Das Unternehmen BIOMX INC kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.